Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Ironwood Pharma ( (IRWD) ) is now available.
Ironwood Pharmaceuticals announced it received a notification from Nasdaq on March 21, 2025, due to a delay in filing its 2024 Annual Report, which led to non-compliance with Nasdaq’s listing rules. The company has until May 20, 2025, to submit a compliance plan, with a potential extension to September 1, 2025, to file the report. The notice does not immediately affect the company’s Nasdaq listing, and Ironwood plans to file the report promptly to regain compliance.
More about Ironwood Pharma
Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases. The company is known for advancing apraglutide, a synthetic GLP-2 analog for short bowel syndrome, and LINZESS, a leading prescription treatment for irritable bowel syndrome with constipation and chronic idiopathic constipation.
YTD Price Performance: -66.28%
Average Trading Volume: 3,311,952
Technical Sentiment Signal: Buy
Current Market Cap: $233.6M
Learn more about IRWD stock on TipRanks’ Stock Analysis page.